TIDMKNB

RNS Number : 7528U

Kanabo Group PLC

07 December 2021

Kanabo Group Plc

("Kanabo" or the "Company")

Submission for Medical Bioavailability and Efficacy Trial

Bioavailability and Efficacy Trial to Commence using VapePod

Kanabo Group Plc (LSE:KNB), a medical cannabis and R&D Company that focuses on the distribution of cannabis-derived products for medical patients and wellness CBD consumers, announces it has applied to undertake a bioavailability and efficacy trial (the "Trial") of its proprietary Cannabis inhalation formulas used in conjunction with its VapePod delivery device.

The outcome of this 3-month trial will be:

1. An approval to sell the medical vape and formulas in Israel - this will be the first cannabis vape cartridges in the Israeli market.

2. To support sales in UK and Germany by providing physicians and the medical establishments with evidence-based medicine.

3. This is expected to be the first clinical trial for a cannabis vape pen in the world, that will provide bioavailability and efficacy data.

Kanabo, in partnership with Seach Medical Group, has submitted a clinical trial protocol for approval at the Hadassah Medical Centre and subsequent review by the Helsinki Committee to test the impact from the inhalation of various Cannabis formulas via its proprietary VapePod delivery device, which dispenses standardised and metered inhalations, on healthy volunteers.

As part of the Trial, participants will undertake a pharmacokinetic ("PK") analysis to define THC and CBD Absorption, Distribution, Metabolism and Excretion ("ADME") following the administration of the Company's proprietary VapePod Formulas.

Once successfully completed, the Trial will help Kanabo target the rapidly growing segments of the medicinal Cannabis market for patients who wish to manage their pain using a clean and measurable method of treatment.

Avihu Tamir, Kanabo's CEO commented : " This is a ground-breaking trial which will evaluate the bioavailability and efficacy of Cannabis-based inhalation formulas administered via Kanabo's VapePod medical device. It is an important milestone as it will help us with our ongoing efforts to allow specialist consultants to prescribe a metered dose of medicinal cannabis that is healthier for patients than the alternative which is typically smoking."

For further information, please visit http://www.kanabogroup.com/ or contact the following:

 
 Kanabo Group Plc 
 Avihu Tamir, CEO                                        Via Vox Markets 
 Peterhouse Capital Ltd 
 Eran Zucker (Financial Adviser)                         Tel: +44 (0)20 7469 0930 
 Lucy Williams / Charles Goodfellow (Corporate Broker)   Tel: +44 (0)20 7469 0930 
 Vox Markets (Investor Relations) 
 Kat Perez                                               KanaboGroup@voxmarkets.co.uk

About Kanabo Group Plc

Kanabo Group Plc is an R&D company currently selling a range of wellness CBD Products in the Primary Markets and Medical Cannabis Products. The company's core strategy is to increase revenues from the sale of its Retail CBD Products in the wellness sector and to grow the Kanabo brand through its marketing initiatives.

About Seach Medical Group

The Seach Medical Group is a pioneer in the field of medical cannabis in Israel since 2008. Seach now has experience, gained over the past decade, with a global network of strategic partnerships and clinical trials.

About Hadassah University Medical Centre

The Trial will be conducted at the Hadassah University Medical Centre ("Hadassah"). Hadassah was first established in 1918 as a gift from the Rothschild family, which has now expanded to include two University Hospitals with over 1,000 beds, thirty-one operating theatres, nine intensive care units and five schools of allied medial professions. Hadassah's physicians and scientists are regularly engaged in a wide variety of clinical research projects and trials.

About the Helsinki Committee

The Helsinki Committee's work is to authorise medical research and trials on humans, which aim to expand medical knowledge and improve the outcomes of medical treatment.

The work of the Helsinki Committee on this submission will ensure the integrity of the Trail and ensure it is carried out in accordance with the approved medical ethics guidelines outlined in the Declaration of Helsinki and the various international conventions concerning medical experiments on humans, and in accordance with the guidelines, laws and regulations which were legislated by the Israeli parliament and the Ministry of Health with the aim of regulating the issue of medical trials on humans.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFQLLBFLLLFBD

(END) Dow Jones Newswires

December 07, 2021 02:00 ET (07:00 GMT)

Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Kanabo.
Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Kanabo.